Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Inclusion Criteria:

• Agree to participate in the study and give written informed consent

• At least 6 points on the Jackson scale according to physical examination andquestioning (sneezing, runny nose, nasal obstruction, sore throat, cough, headache,malaise, and chills).

• Symptoms associated with the common cold with maximum of 3 days since presentation

• Women of childbearing potential under a medically acceptable method of contraception

• At the discretion of the Principal Investigator (PI) or treating physician,treatment with the researching product is indicated and may present clinical benefit

Exclusion Criteria:

• Patients in whom respiratory symptoms are suspected to be of bacterial origin andgenerate a clinical picture compatible with: Rhinosinusitis (muco-purulentdischarge, headache or facial pain, etc.), lower respiratory tract disease (wheezing, crackles, productive cough, etc.), acute otitis media (otalgia, purulentdischarge from the ear, auditory discomfort, etc.).

• Patients participating in another clinical trial involving an investigationaltreatment or participation in one within 4 weeks prior to study start

• Patients in whom participation in the study may be influenced (employmentrelationship with the research site or sponsor, inmates, etc.)

• At medical discretion, a disease that affects prognosis and prevents outpatientmanagement, for example, but not limited to: end-stage cancer, kidney, heart,respiratory or liver failure, mental illness or with scheduled surgical or hospitalprocedures

• History/presence of any disease or condition that, in the opinion of theInvestigator, could pose a risk for the patient or confusing the efficacy and safetyof the investigational product

• Patients in whom the study drug is contraindicated for medical reasons

• Patients with allergy or hypersensitivity to the active substance of the studydrugs, related products or excipients (Ibuprofen of Loratadine)

• Pregnant women, women breastfeeding or planning a pregnancy during the conductingthe study

• Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn'sdisease, Ulcerative Colitis, etc.)

• History of chronic liver failure Child-Pugh A, B, and/or C

• History of acute renal failure (glomerular filtration rate <30 ml/min/1.72 m2)

• Patients with a history of alcohol or drug abuse in the last year

• Patients with symptoms suggestive of COVID-19 infection (fever, cough, dyspnea)and/or contact in the last 14 days with a suspected or positive patient for COVID-19